Sotrovimab vs placebo
Clinical progression: IMV or death (≥ 7 WHO scale) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Sotrovimab showed no clear difference in clinical progression: IMV or death (≥ 7 WHO scale) compared with placebo (low certainty).
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes onlyRR 0.14 [0.01, 2.76]1 study · 583 participantsLow